SMLE Clinical Reasoning Walkthrough: Diagnosing Resistant Hypertension

Clinical Case

A 45-year-old male presents to the primary care clinic for a routine follow-up of his hypertension. He reports strict adherence to his medication regimen and a low-sodium diet, but states he has been feeling unusually fatigued and experiencing occasional muscle cramps in his legs over the past two months. His current medications include maximum tolerated doses of amlodipine, lisinopril, and hydrochlorothiazide. His blood pressure today is 168/102 mmHg, and his heart rate is 78 bpm. Physical examination is unremarkable, with no abdominal bruits, peripheral edema, or cushingoid features. Laboratory investigations reveal a serum sodium of 146 mEq/L, a serum potassium of 2.8 mEq/L, and normal serum creatinine. Which of the following is the most appropriate next step in the diagnosis of this patient's condition?

A) Plasma aldosterone concentration to plasma renin activity ratio
B) Renal ultrasound with Doppler
C) 24-hour urine free cortisol
D) Plasma fractionated metanephrines

When approaching a patient with hypertension in the clinical setting or within the rigorous framework of the SMLE, the first step is determining whether the hypertension is primary (essential) or secondary. This patient presents with resistant hypertension, defined clinically as blood pressure that remains above goal despite the concurrent use of three antihypertensive agents of different classes (one of which is a diuretic). Coupled with the classic presentation of spontaneous hypokalemia (potassium of 2.8 mEq/L) and muscle cramps, the index of suspicion for secondary hypertension must be extremely high. Our initial clinical focus must shift from merely adding a fourth antihypertensive agent to actively screening for an underlying endocrine etiology. For a comprehensive approach to tackling such complex vignettes systematically, candidates should review How to Prepare for the SMLE: The Ultimate 2026 Study Plan and Strategy Guide.

Option-by-Option Analysis

A) Plasma aldosterone concentration to plasma renin activity ratio: This is the correct initial screening test. The clinical triad of resistant hypertension, hypokalemia, and metabolic alkalosis is the hallmark of primary hyperaldosteronism (Conn's syndrome). In this condition, an adrenal adenoma or bilateral adrenal hyperplasia autonomously secretes excess aldosterone. This excess suppresses renin production via negative feedback, resulting in a significantly elevated PAC/PRA ratio (typically > 20). Identifying this early is crucial, which is why it is heavily tested in the SMLEREVISE High-Yield Question Bank.

B) Renal ultrasound with Doppler: This option is incorrect. While renal artery stenosis (RAS) is a common cause of secondary hypertension, it typically presents with an abdominal bruit, flash pulmonary edema, or an acute and severe elevation in serum creatinine after the initiation of an ACE inhibitor (like lisinopril) or an ARB. Furthermore, while RAS can cause secondary hyperaldosteronism (elevated aldosterone and elevated renin), it does not align with the classic, isolated spontaneous hypokalemia seen without severe renal function impairment in this vignette.

C) 24-hour urine free cortisol: This option is incorrect. A 24-hour urine free cortisol is the preferred initial screening test for hypercortisolism (Cushing's syndrome). While Cushing's syndrome does cause secondary hypertension and can occasionally cause hypokalemia due to cortisol's cross-reactivity with mineralocorticoid receptors at very high levels, this patient lacks the classic phenotypic features (e.g., central obesity, moon facies, buffalo hump, purple striae, proximal muscle weakness). You can find detailed visual aids for these features in our SMLEREVISE High-Yield Notes (HYN).

D) Plasma fractionated metanephrines: This option is incorrect. This is the screening test of choice for pheochromocytoma, a catecholamine-secreting tumor of the adrenal medulla. Patients with pheochromocytoma classically present with paroxysmal hypertension accompanied by the classic triad of episodic headaches, sweating, and tachycardia. Our patient has persistent, non-episodic hypertension, no tachycardia (HR 78 bpm), and no diaphoresis, making this diagnosis highly unlikely.

Correct Answer & Explanation

The correct answer is A) Plasma aldosterone concentration to plasma renin activity ratio. In the 2025/2026 SMLE guidelines, any patient presenting with resistant hypertension (uncontrolled on 3+ drugs including a diuretic) accompanied by unprovoked hypokalemia must be screened for primary hyperaldosteronism. The autonomous secretion of aldosterone from the adrenal cortex causes increased sodium reabsorption and potassium/hydrogen excretion in the distal nephron. This leads to volume expansion, hypertension, hypokalemia, and a mild metabolic alkalosis. The volume expansion suppresses renal renin release, leading to the diagnostically crucial high aldosterone and low renin state.

The underlying diagnostic mechanism follows a strict three-step protocol that candidates must memorize. First, Screening is performed using the PAC/PRA ratio. A positive screen (ratio > 20, with PAC > 15 ng/dL) mandates the second step: Confirmation. Confirmatory testing involves demonstrating inappropriate aldosterone secretion despite a suppressive stimulus, typically achieved via an oral sodium loading test or saline infusion test. If aldosterone remains elevated (non-suppressible), primary hyperaldosteronism is confirmed. The final step is Subtyping via an adrenal CT scan followed by adrenal venous sampling to differentiate between a unilateral adenoma (which is managed surgically) and bilateral adrenal hyperplasia (which is managed medically with mineralocorticoid receptor antagonists like spironolactone).

To consistently excel in these questions, candidates should integrate this stepwise algorithm into their daily review using SMLEREVISE High-Yield Notes (HYN) and test their speed under timed conditions using SMLEREVISE Grand Mocks. Time management and rapid pattern recognition of these "next best step" questions are vital for success. For further insights into maximizing your performance on exam day, be sure to read Mastering the SMLE: Expert Strategies and Test-Day Excellence.

Sina AI Memory Pearl

When the SMLE tests secondary hypertension, remember the "CHAPS" mnemonic: Cushing's, Hyperaldosteronism, Aorta coarctation, Pheochromocytoma, and Stenosis of the renal arteries. To narrow it down instantly to Hyperaldosteronism, use the Sina AI shortcut: "Aldo Saves Sodium and Kicks out Potassium & Hydrogen." If you see high blood pressure (Saved Sodium/Volume) paired with low K+ (Kicked out Potassium) and high bicarbonate (Kicked out Hydrogen = alkalosis), the diagnosis is Primary Hyperaldosteronism until proven otherwise.

Understanding these high-yield discriminators is what elevates a candidate from an average score to the top percentiles. Mastery of these physiological concepts directly correlates with higher passing margins. To understand how these high-yield topics influence your final standard score, check out SMLE Score Distribution and Passing Rates: The Definitive 2026 Guide.

References

• Saudi Commission for Health Specialties (SCFHS). (2025). SMLE Internal Medicine Blueprint and Clinical Guidelines.
• Funder, J. W., et al. (2016). The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism.
• UpToDate. (2025). Diagnosis of primary aldosteronism. Wolters Kluwer.
• SMLEREVISE Medical Editorial Board. (2025). High-Yield Internal Medicine for the SMLE.